Special K: Ketamine, From Party Drug To Depression Medication
When you picture the drug ketamine, you might think of that stoner you knew in high school or a bunch of people popping pills in neon-lit clubs.
Looking Back, Looking Forward: A Revolution in Psychiatry – May 9, 2019
Event: Looking Back, Looking Forward: A Revolution in Psychiatry – May 9, 2019 – View Invitation
Highlights from 1.17.19 Cocktail and Conversation Event
Highlights from 1.17.19 Cocktail and Conversation Event – Watch video and read transcript: An accurate diagnosis is a path to hope, Elizabeth Errico MA, LPC, NCC
Join us for an evening of Cocktails & Conversation to learn about the Juvenile Bipolar Research Foundation
We invite you to come learn more about juvenile bipolar disorder and some of the groundbreaking research JBRF is doing, including our sponsored researchers’ work to identify the Fear of Harm (FOH) syndrome, a specific diagnosis that may affect countless young people who have juvenile bipolar disorder. You will also learn about an affordable treatment discovery for FOH patients that can give them, and their families, hope for a more normal life.
The Difference a Diagnosis Makes: How Understanding Fear of Harm Syndrome May Help Save Your Child
Alice* is artistic, intelligent and on her third
school placement. Her parents remember that she was always very hot as a baby. Growing up she would constantly kick off the bed covers, often waking up in a pool of sweat with terrifying nightmares that no one could explain. She was often afraid to go to sleep. She would worry about everything, howled when she was separated from her parents and often demanded to sleep in their bed.
The JBRF has isolated and defined the Fear of Harm BPD phenotype
The JBRF has isolated and defined the Fear of Harm BPD phenotype, the first psychiatric illness to be associated with a heritable, physical biomarker. Click to view info graphic.
The First Longitudinal Study Using Intranasal Ketamine in the Treatment of the Fear of Harm Phenotype
This landmark study codifies years of clinical experience with intranasal ketamine which goes beyond the current research base to provide preliminary evidence of efficacy and safety over an extended period.
Q&A on the significance of the longitudinal study of intranasal ketamine in a novel phenotype of bipolar disorder
Clinical experience using intranasal ketamine in the longitudinal treatment of juvenile bipolar disorder with fear of harm phenotype. Papolos D1, Frei M2, Rossignol D3, Mattis S4, Hernandez-Garcia LC5, Teicher MH5.J Affect Disord. 2017 Aug 30. 1. Were you surprised by your findings, why, why not? I was surprised by the magnitude of the effect when…
In Memory of Dr. Cleland C. Landolt, MD, FACS, FACC, FACP
Dr. Cleland C. Landolt, M.D., 68, of San Diego, CA, passed away on June 19, 2017. He died of congestive heart failure. Cle is survived by his former spouse, Kendra Tucker, their sons Cole and Reilly, his sisters Wendy and Sally, and his brothers Peter, Bruce and Matthew. He is pre-deceased by his father, Dr.…